Digital medical illustration of kidneys with inflammation, representing kidney disease research and treatment innovation by ZyVersa Therapeutics.

Compassionate use approved: A patient with ultra-rare ApoCII amyloidosis is now receiving #ZyVersa #ZVSA investigational kidney drug VAR 200 under FDA emergency authorization. A bold step in precision medicine and a hopeful sign for those with no other options.
prismmarketview.com/zyversa-ther...